Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
